These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 34787787)

  • 1. Incidence of thrombotic complications related to weight-based dosing of activated prothrombin complex concentrate (aPCC) for reversal of apixaban and rivaroxaban in obese patients.
    Whitaker C; McKinney A; Bollig R; Hieb N; Roberts RF; Rowe AS
    J Thromb Thrombolysis; 2022 May; 53(4):861-867. PubMed ID: 34787787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of adults with intracranial hemorrhage on apixaban or rivaroxaban with prothrombin complex concentrate products.
    Castillo R; Chan A; Atallah S; Derry K; Baje M; Zimmermann LL; Martin R; Groysman L; Stern-Nezer S; Minokadeh A; Nova A; Huang W; Cang W; Schomer K
    J Thromb Thrombolysis; 2021 Jan; 51(1):151-158. PubMed ID: 32500220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhages.
    Pham H; Medford WG; Horst S; Levesque M; Ragoonanan D; Price C; Colbassani H; Piper K; Chastain K
    Am J Emerg Med; 2022 May; 55():38-44. PubMed ID: 35272069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
    Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
    Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Activated Prothrombin Complex Concentrate for Reversal of the Anticoagulant Effect of Apixaban and Rivaroxaban in Patients with Major Bleeding.
    Sheikh-Taha M; Clark HL; Crawley RM
    Clin Drug Investig; 2023 Nov; 43(11):883-888. PubMed ID: 37882941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversal of Apixaban and Rivaroxaban Using Activated Prothrombin Complex Concentrates in Patients with Major Bleeding.
    Sheikh-Taha M; Crawley RM
    Am J Cardiovasc Drugs; 2020 Jun; 20(3):295-299. PubMed ID: 31709499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage.
    Vestal ML; Hodulik K; Mando-Vandrick J; James ML; Ortel TL; Fuller M; Notini M; Friedland M; Welsby IJ
    J Thromb Thrombolysis; 2022 Jan; 53(1):167-175. PubMed ID: 34101050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emergent reversal of oral factor Xa inhibitors with four-factor prothrombin complex concentrate.
    Lipari L; Yang S; Milligan B; Blunck J
    Am J Emerg Med; 2020 Dec; 38(12):2641-2645. PubMed ID: 33041150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rivaroxaban Versus Warfarin for Stroke Prevention and Venous Thromboembolism Treatment in Extreme Obesity and High Body Weight.
    Perales IJ; San Agustin K; DeAngelo J; Campbell AM
    Ann Pharmacother; 2020 Apr; 54(4):344-350. PubMed ID: 31672028
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison of 4-factor prothrombin complex concentrate and andexanet alfa for reversal of apixaban and rivaroxaban in the setting of intracranial hemorrhage.
    Lipski M; Pasciolla S; Wojcik K; Jankowitz B; Igneri LA
    J Thromb Thrombolysis; 2023 Apr; 55(3):519-526. PubMed ID: 36566473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Obesity on Warfarin Reversal With Fixed-Dose Factor VIII Inhibitor Bypassing Activity (aPCC).
    McKinney AL; Dailey LM; McMillen JC; Rowe AS
    Ann Pharmacother; 2021 Jul; 55(7):856-862. PubMed ID: 33094635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of apixaban- and rivaroxaban-associated major bleeding using 4-factor prothrombin complex concentrate.
    Sheikh-Taha M
    Intern Emerg Med; 2019 Mar; 14(2):265-269. PubMed ID: 30414056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Factor Xa Inhibitor Reversal with Prothrombin Complex Concentrate in Patients with Traumatic Brain Injuries.
    Cooksey GE; Hamilton LA; McMillen JC; Griffard JH; Rowe AS
    Neurocrit Care; 2022 Oct; 37(2):471-478. PubMed ID: 35624388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factor Xa Inhibitor-Related Intracranial Hemorrhage: Results From a Multicenter, Observational Cohort Receiving Prothrombin Complex Concentrates.
    Panos NG; Cook AM; John S; Jones GM;
    Circulation; 2020 May; 141(21):1681-1689. PubMed ID: 32264698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bleeding rates of Veterans taking apixaban or rivaroxaban for atrial fibrillation or venous thromboembolism.
    Howe Z; Naville-Cook C; Cole D
    J Thromb Thrombolysis; 2019 Feb; 47(2):280-286. PubMed ID: 30449001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patients with higher body mass index treated with direct / novel oral anticoagulants (DOAC / NOAC) for atrial fibrillation experience worse clinical outcomes.
    Lucijanic M; Jurin I; Jurin H; Lucijanic T; Starcevic B; Skelin M; Glasnovic A; Catic J; Jurisic A; Hadzibegovic I
    Int J Cardiol; 2020 Feb; 301():90-95. PubMed ID: 31748190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prothrombin Complex Concentrate before Urgent Surgery in Patients Treated with Rivaroxaban and Apixaban.
    Barzilai M; Kirgner I; Steimatzky A; Salzer Gotler D; Belnick Y; Shacham-Abulafia A; Avivi I; Raanani P; Yahalom V; Nakav S; Varon D; Yussim E; Bachar GN; Spectre G
    Acta Haematol; 2020; 143(3):266-271. PubMed ID: 31610537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prothrombin complex concentrates for the urgent reversal of apixaban and rivaroxaban: an Australian retrospective cohort study.
    Wallwork S; Wang Y; Chaiwatanatorn K; Cole-Sinclair M
    Intern Med J; 2023 May; 53(5):803-811. PubMed ID: 34779569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation.
    Ray WA; Chung CP; Stein CM; Smalley W; Zimmerman E; Dupont WD; Hung AM; Daugherty JR; Dickson A; Murray KT
    JAMA; 2021 Dec; 326(23):2395-2404. PubMed ID: 34932078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversal of apixaban and rivaroxaban with andexanet alfa prior to invasive or surgical procedures.
    Bradshaw PG; Keegan SP; Droege ME; Dykes NJH; Ernst NE; Foertsch MJ; Makley AT; Mueller EW; Philpott CD; Srinivasan V; Winter JB; Goodman MD; Droege CA
    Pharmacotherapy; 2022 Oct; 42(10):780-791. PubMed ID: 36073083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.